Congenital Heart Defect
0
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Baxter InternationalCoSeal Surgical Spray Group
MedtronicNIRS evaluation
Cook MedicalHuman Milk Derived Fortifier
Clinical Trials (3)
Total enrollment: 151 patients across 3 trials
Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
Start: Aug 2011Est. completion: Aug 201535 patients
Phase 2Completed
NIRS in Congenital Heart Defects - Correlation With Echocardiography
Start: Oct 2019Est. completion: Dec 2025100 patients
N/ARecruiting
Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology
Start: Jul 2016Est. completion: Oct 202216 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 151 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.